Nová antitrombotika v prevenci zilní tromboembolie a nové protidestickové léky
[New antithrombotics in the prevention of venous thromboembolia and new anti-platelet drugs]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article, Review
PubMed
21957766
- MeSH
- Fibrinolytic Agents therapeutic use MeSH
- Platelet Aggregation Inhibitors therapeutic use MeSH
- Humans MeSH
- Venous Thromboembolism prevention & control MeSH
- Check Tag
- Humans MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Fibrinolytic Agents MeSH
- Platelet Aggregation Inhibitors MeSH
We first present a brief overview of new antithrombotic agents that are assumed to replace coumarines and heparin in many indications; this overview provides information on pentasaccharides, direct thrombin inhibitors and direct factorXa inhibitors. Secondly, since the new drugs with antiplatelet effect act through blockade of the reactions involved in blood platelet activation, we review and discuss the substances that interfere with this process. The current antiplatelet therapy focuses mainly on an inhibition of platelet aggregation stimulated by ADP, reducing the risk of arterial occlusions.
